Unither Pharmaceuticals, a global leader in sterile single dose technology, acquires Nanjing Ruinian Best Pharmaceutical
The Background Unither Pharmaceuticals, a global leader in sterile single dose technology, announced the acquisition of Nanjing Ruinian Best Pharmaceutical (NRB), a Chinese pharmaceutical company. With the completion of this acquisition, Unither will further strengthen its position as the global leader in sterile single doses produced with Blow-Fill-Seal (BFS) technology.
The Deal Unither, a global leader in B/F/S technology based CDMO, successfully concluded its agreement with Wuxi Jinyuan for the acquisition of NRB. The deal is to be executed in three steps and will allow Unither to own 100% of NRB eventually. Besides, Unither is estimated to invest up to USD 100 million into NRB, in JNDZ to bring it to a world class pharmaceutical company. “We are delighted to welcome this company into our group. Nanjing Ruinian Best will allow us to speed up our development and strengthen our activities in China, in line with our strategy to manufacture drugs closer to our customers” said Eric Goupil, Group President of Unither.
The Partners Unither Pharmaceuticals develops and manufactures pharmaceutical products on behalf of its customers. Unither differentiates itself by specializing in certain pharmaceutical forms, in particular sterile single unit dose, and by offering turnkey products to its customers, that they will be able to sell under their own brand. Unither is one of France's leading pharmaceutical manufacturers with a turnover of nearly € 300 million in 2018. The Group has four production plants in France, one in the United States, one in Brazil and one development center in Bordeaux. Its deep understanding of patient needs and its experience in product development and process implementation ensures the best conditions for our customers’ market success.
Nanjing Ruinian Best Pharmaceutical specializes in the development and production of solid and liquid form pharmaceutical products, with an annual revenue around € 10 million. It is based in Nanjing, Jiangsu Province, and has 130 employees. It is owned by Wuxi Jinyuan Industrial Investment Development Group, an investment holding company located in Binhu district, in Wuxi.
The Perspective In near term, Unither will focus on improving the quality, marketing, and development capabilities of NRB, to upgrade its current operational efficient and financial robustness. Then, Unither will expand production capacity by adding new B/F/S lines, production space and additional supply chain facilities to make it the hub for its China, and Asia access. For the long term, Unither aims to make this location a world class B/F/S manufacture for not only eye drops but also raspatory and other advanced pharmaceutical products.